tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Encephalitis D004660 15 associated lipids
Encephalomyelitis, Autoimmune, Experimental D004681 26 associated lipids
Endomyocardial Fibrosis D004719 4 associated lipids
Enterobacteriaceae Infections D004756 5 associated lipids
Epidermolysis Bullosa D004820 3 associated lipids
Epididymitis D004823 1 associated lipids
Epilepsy, Temporal Lobe D004833 4 associated lipids
Erythema D004890 22 associated lipids
Erythema Nodosum D004893 5 associated lipids
Leukemia, Erythroblastic, Acute D004915 41 associated lipids
Erythroplasia D004919 1 associated lipids
Esophageal Perforation D004939 1 associated lipids
Exanthema D005076 11 associated lipids
Eye Diseases D005128 12 associated lipids
Facial Dermatoses D005148 7 associated lipids
Facial Neoplasms D005153 3 associated lipids
Fatigue D005221 10 associated lipids
Fatty Liver D005234 48 associated lipids
Femur Head Necrosis D005271 5 associated lipids
Fetal Hypoxia D005311 3 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Tanabe K et al. Prospective analysis and successful treatment of thrombotic microangiopathy in renal allografts under tacrolimus immunosuppression. 2001 Nov-Dec Transplant. Proc. pmid:11750571
Claesson K et al. Lipoprotein patterns in renal transplant patients: a comparison between FK 506 and cyclosporine A patients. 1998 Transplant. Proc. pmid:9636524
Lye WC Primary tacrolimus-based immunosuppression in renal allograft recipients: a single center experience. 2000 Transplant. Proc. pmid:11119898
Peddi VR et al. Tacrolimus eliminates acute rejection as a major complication following simultaneous kidney and pancreas transplantation. 1998 Transplant. Proc. pmid:9532151
Ben-Ari Z et al. Comparison of tacrolimus with cyclosporin as primary immunosuppression in patients with hepatitis C virus infection after liver transplantation. 2003 Transplant. Proc. pmid:12644067
Gutiérrez Sánchez MJ et al. Optimization of immunosuppression by switching from azathioprine to enteric-coated mycophenolate sodium in stable kidney transplant patients. 2009 Jul-Aug Transplant. Proc. pmid:19715907
Rafecas A et al. Immunosuppression with calcineurin inhibitors and polyclonal antibodies in liver transplantation. 2002 Transplant. Proc. pmid:11959209
Aptaramanov B et al. A comparison of mycophenolate mofetil with mycophenolate sodium in renal transplant recipients on tacrolimus-based treatment. 2011 Transplant. Proc. pmid:21486609
Ma A et al. Immunological evaluation of combination therapy with tacrolimus and sirolimus on long-term allograft survival in nonhuman primates. 2005 Jan-Feb Transplant. Proc. pmid:15808578
Waller JR et al. Mycophenolate mofetil inhibits intimal hyperplasia and attenuates the expression of genes favouring smooth muscle cell proliferation and migration. 2005 Jan-Feb Transplant. Proc. pmid:15808582
Tabasco-Minguillan J et al. Long-term insulin requirement after liver transplantation with FK 506 in American veterans. 1993 Transplant. Proc. pmid:7679839
Abu-Elmagd KM et al. Strategy of FK 506 therapy in liver transplant patients: effect of graft function. 1991 Transplant. Proc. pmid:1721272
Kusne S et al. Infections during a randomized trial comparing cyclosporine to FK 506 immunosuppression in liver transplantation. 1992 Transplant. Proc. pmid:1371626
Tanaka M et al. Tacrolimus (FK 506)-dependent tolerance after liver and heart xenotransplantation: inhibition of humoral response and acceptance of donor organs. 1996 Transplant. Proc. pmid:8623341
Ye Q et al. Functional analysis of hamster kidney xenografts in the rat: possible functional incompatibility and adaptation of hamster kidney grafts in a xenogenic rat environment. 1996 Transplant. Proc. pmid:8623350
Nalesnik MA et al. The effect of FK 506 and CyA on the Lewis rat renal ischemia model. 1990 Transplant. Proc. pmid:1689911
Faivre L et al. FK 506 dose in transplantation: from theory to practice. 2001 Transplant. Proc. pmid:11406256
Lang M et al. Impact of immunosuppression in liver transplantation across a positive crossmatch. 1998 Transplant. Proc. pmid:9636595
Lo CM et al. More effective immunosuppression with the use of FK506 after liver transplantation. 2000 Transplant. Proc. pmid:11120161
van Hooff JP et al. Dosing and management guidelines for tacrolimus in renal transplant patients. 1999 Transplant. Proc. pmid:10576046
Díaz-Molina B et al. Effect of CYP3A5, CYP3A4, and ABCB1 genotypes as determinants of tacrolimus dose and clinical outcomes after heart transplantation. 2012 Transplant. Proc. pmid:23146479
Hatori M et al. Clinicopathologic examination of no-episode biopsies in well-functioning renal allografts. 1998 Transplant. Proc. pmid:9474971
Watarai Y et al. Effect of tacrolimus and cyclosporine on renal microcirculation and nitric oxide production. 2004 Transplant. Proc. pmid:15518773
Donnelly JG and Soldin SJ Purification of a 50- to 58-kDa immunophilin from human spleen and a Jurkat T-cell line capable of binding cyclosporine A, FK 506, and rapamycin. 1991 Transplant. Proc. pmid:1721305
Woo J et al. Effects of FK 506 and low concentration cyclosporine on human lymphocyte activation antigen expression: a flow cytometric analysis. 1990 Transplant. Proc. pmid:1697113
Telkes G et al. Kidney transplantation in hereditary coproporphyria using tacrolimus and mycophenolate mofetil: a case report. 2013 Transplant. Proc. pmid:24315002
Ziolkowski J et al. Effect of immunosuppressive regimen on acute rejection and liver graft function. 2003 Transplant. Proc. pmid:14529915
Teisseyre J et al. Elevated tacrolimus levels during diarrhea in children after liver transplantation. 2003 Transplant. Proc. pmid:14529919
Kato T et al. FK506 may suppress liver injury during the early period following living-related liver transplantation. 2003 Transplant. Proc. pmid:12591316
Takai K et al. Delayed graft function after renal transplantation from a non-heart-beating donors. 2003 Transplant. Proc. pmid:12591320
González-Pinto IM et al. Five-year follow-up of a trial comparing Tacrolimus and cyclosporine microemulsion in liver transplantation. 2005 Transplant. Proc. pmid:15919441
Hesselink DA et al. The use of cyclosporine in renal transplantation. 2004 Transplant. Proc. pmid:15041316
Ã…berg F et al. Asymptomatic De Novo Inflammatory Bowel Disease Late After Liver Transplantation for Primary Sclerosing Cholangitis: A Case Report. 2015 Transplant. Proc. pmid:26680092
Bäckman L et al. Chronic nephrotoxicity of FK 506 after liver transplantation. 1994 Transplant. Proc. pmid:7518159
Bäckman L et al. Whole blood and plasma levels of FK 506 after liver transplantation: correlation with toxicity. 1994 Transplant. Proc. pmid:7518160
Yagihashi A et al. Changes in cell surface markers in human small bowel transplantation with FK 506. 1992 Transplant. Proc. pmid:1376522
Sakimoto H et al. Prolonged survival of hamster-to-rat pancreas xenografts by FK 506 and splenectomy. 1995 Transplant. Proc. pmid:7533394
Abu-Elmagd K et al. Management of intestinal transplantation in humans. 1992 Transplant. Proc. pmid:1376523
Celli S et al. Mechanisms of protection from humoral rejection by a xenografted liver. 1995 Transplant. Proc. pmid:7533395
Lewis WD et al. FK 506 rescue therapy in liver transplant recipients with drug-resistant rejection. 1991 Transplant. Proc. pmid:1721336
Woodle ES et al. FK 506: reversal of humorally mediated rejection following ABO-incompatible liver transplantation. 1991 Transplant. Proc. pmid:1721337
Jain AK et al. Interaction between tacrolimus and antiretroviral agents in human immunodeficiency virus-positive liver and kidney transplantation patients. 2002 Transplant. Proc. pmid:12176474
Esposito C et al. Effect of calcineurin inhibitors on extracellular matrix turnover in isolated human glomeruli. 2004 Transplant. Proc. pmid:15110634
Metcalfe SM et al. In vitro transcription and translation of the tumour suppressor protein P53: qualitative and quantitative effects of FK506 and rapamycin. 1998 Transplant. Proc. pmid:9865315
Dierickx D et al. Thrombotic microangiopathy following intestinal transplantation: a single center experience. 2010 Jan-Feb Transplant. Proc. pmid:20172285
Pape L et al. Long-term stable glomerular filtration rate achieved with tacrolimus in pediatric renal transplantation. 2002 Transplant. Proc. pmid:12270367
Prasad GV et al. Role of dietary salt intake in posttransplant hypertension with tacrolimus-based immunosuppression. 2005 Transplant. Proc. pmid:15919496
Nüssler NC et al. CD8+ host cells infiltrate the intestinal mucosa after allogeneic small bowel transplantation even in the absence of acute rejection. 1996 Transplant. Proc. pmid:8907898
van Hooff JP et al. Benelux experience with a combination of tacrolimus and mycophenolate mofetil: 4-year results. 2002 Transplant. Proc. pmid:12176498
Scantlebury VP et al. Pediatric kidney transplantation at the University of Pittsburgh. 1994 Transplant. Proc. pmid:7509095
Malaise J et al. Immunosuppressive drugs after simultaneous pancreas-kidney transplantation. 2005 Jul-Aug Transplant. Proc. pmid:16182827
Malaise J et al. Tacrolimus compared with cyclosporine microemulsion in primary simultaneous pancreas-kidney transplantation: the EURO-SPK 3-year results. 2005 Jul-Aug Transplant. Proc. pmid:16182828
Todo S et al. Clinical small bowel or small bowel plus liver transplantation under FK 506. 1991 Transplant. Proc. pmid:1721369
Tzakis AG et al. Use of FK 506 in pediatric patients. 1991 Transplant. Proc. pmid:1703353
Zegarska J et al. Evaluation of the Relationship Between Concentrations of Tacrolimus Metabolites, 13-O-Demethyl Tacrolimus and 15-O-Demethyl Tacrolimus, and Clinical and Biochemical Parameters in Kidney Transplant Recipients. 2018 Transplant. Proc. pmid:30177142
Takeda M et al. Immunologic factors contributing to acute rejection in lungs xenotransplanted between primates. 1998 Transplant. Proc. pmid:9838670
Fukushima N et al. Prolonged survival of pig cardiac xenografts in baboons by sequential cardiac transplantation. 1998 Transplant. Proc. pmid:9838671
Schulz T et al. Mycophenolate mofetil/prednisolone/single-shot ATG with tacrolimus or cyclosporine in pancreas/kidney transplantation: first results of an ongoing prospective randomized trial. 1999 Feb-Mar Transplant. Proc. pmid:10083251
Burke GW et al. Donor bone marrow infusion in simultaneous pancreas/kidney transplantation with OKT3 induction: evidence for augmentation of chimerism. 1997 Feb-Mar Transplant. Proc. pmid:9123275
Becker G et al. Tacrolimus (FK 506) therapy in simultaneous pancreas kidney transplantation. 1996 Transplant. Proc. pmid:8962228
Baran DA et al. Tacrolimus and new onset diabetes mellitus: the effect of steroid weaning. 2002 Transplant. Proc. pmid:12176547
Tsuchiya T et al. Effect of conversion from twice-daily to once-daily tacrolimus on glucose intolerance in stable kidney transplant recipients. 2012 Transplant. Proc. pmid:22310593
Büttemeyer R et al. Peripheral nerve allotransplant immunosuppressed with FK 506: preliminary results. 1995 Transplant. Proc. pmid:7536979
Wierzbicka A et al. Lipid, carbohydrate metabolism, and antioxidant status in children after liver transplantation. 2007 Transplant. Proc. pmid:17580179
Lopez OL et al. Neuropathologic findings in liver transplantation: a comparative study of cyclosporine and FK 506. 1991 Transplant. Proc. pmid:1721400
Takaya S et al. Use of prostaglandin E1 in crossmatch-negative liver transplant recipients treated with FK 506. 1993 Transplant. Proc. pmid:7685953
Yasunami Y et al. Effects of a novel immunosuppressive agent, FK-506, on islet allograft survival in the rat. 1989 Transplant. Proc. pmid:2468234
Orsenigo R et al. FK506 and SMS 201-995: effect on heterotopic heart transplantation in rats. 2001 Feb-Mar Transplant. Proc. pmid:11266956
Nakao A et al. Cytokine mRNA expression on rat small bowel allograft treated with tacrolimus and simultaneous bone marrow transplantation via the portal vein. 2000 Transplant. Proc. pmid:10995965
Soltero L et al. Coadministration of tacrolimus and ketoconazole in renal transplant recipients: cost analysis and review of metabolic effects. 2003 Transplant. Proc. pmid:12826147
Glanemann M et al. Higher immunosuppressive efficacy of mycophenolate mofetil in combination with FK 506 than in combination with cyclosporine A. 2000 Transplant. Proc. pmid:10812095
McMaster P et al. Liver transplantation: changing goals in immunosuppression. 1998 Transplant. Proc. pmid:9723295
Calne RY The development of immunosuppression: the rapamycin milestone. 2003 Transplant. Proc. pmid:12742463
Fábrega E et al. Effect of immunosuppressant blood levels on serum concentration of interleukin-17 and -23 in stable liver transplant recipients. 2009 Transplant. Proc. pmid:19376417
Sánchez Pérez B et al. Adverse effects on the lipid profile of immunosuppressive regimens: tacrolimus versus cyclosporin measured using C2 levels. 2009 Transplant. Proc. pmid:19376418
Burke GW et al. Steroid-resistant acute rejection following SPK: importance of maintaining therapeutic dosing in a triple-drug regimen. 2002 Transplant. Proc. pmid:12176628
Woeste G et al. Tacrolimus/mycophenolate mofetil vs cyclosporine A/Azathioprine after simultaneous pancreas and kidney transplantation: five-year results of a randomized study. 2002 Transplant. Proc. pmid:12176629
Kishikawa H et al. Low-dose steroid maintenance for renal transplant recipients. 2010 Transplant. Proc. pmid:21168618
Ji SM et al. Rescue therapy by immunoadsorption in combination with tacrolimus and mycophenolate mofetil for C4d-positive acute humoral renal allograft rejection. 2006 Transplant. Proc. pmid:17175303
Gotoh M et al. Tolerance induction by liver grafting and FK 506 treatment in nonhuman primates. 1991 Transplant. Proc. pmid:1721431
Ishikawa M et al. Acetaminophen absorption test as a useful indicator of small intestinal rejection in rats. 1996 Transplant. Proc. pmid:8658911
Valdivia LA et al. Differential survival of hamster-to-rat liver and cardiac xenografts under FK 506 immunosuppression. 1991 Transplant. Proc. pmid:1721432
Kawano K et al. FK506 reduces oxidative hepatic injury following cold ischemic preservation and transplantation. 1996 Transplant. Proc. pmid:8658938
Sanghvi A et al. FK-506 enhances cyclosporine uptake by peripheral blood lymphocytes. 1987 Transplant. Proc. pmid:2445074
Ochiai T et al. Prolongation of canine renal allograft survival by treatment with FK-506. 1987 Transplant. Proc. pmid:2445075
López-Vilella R et al. Incidence of development of obesity after heart transplantation according to the calcineurin inhibitor. Transplant. Proc. pmid:25645789
Peltekian K et al. De novo use of low-dose tacrolimus and sirolimus in liver transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11267318
Ybarra J et al. Reflex sympathetic dystrophy syndrome in renal transplanted patients under immunosuppression with tacrolimus. 2003 Transplant. Proc. pmid:14697943
Gómez G et al. Acute tacrolimus nephrotoxicity in renal transplant patients treated with clarithromycin. 1999 Transplant. Proc. pmid:10500563
Khoury N et al. Posttransplant diabetes mellitus in kidney transplant recipients under tacrolimus immunosuppression. 2000 Transplant. Proc. pmid:11134791
Abou-Jaoude MM et al. Tacrolimus (FK506) versus cyclosporine microemulsion (neoral) as maintenance immunosuppression therapy in kidney transplant recipients. 2005 Transplant. Proc. pmid:16213293
Nossal GJ Summary of the First International FK 506 Congress: perspectives and prospects. 1991 Transplant. Proc. pmid:1721464
Mita A et al. Optimal initial dose of orally administered once-daily extended-release tacrolimus following intravenous tacrolimus therapy after liver transplantation. 2014 Transplant. Proc. pmid:24767351
Reimer J et al. Quality of life after kidney transplantation--the impact of tacrolimus. 2001 Feb-Mar Transplant. Proc. pmid:11267573
McLaughlin GE et al. Effect of aminophylline on urine flow in children with tacrolimus-induced renal insufficiency. 2000 Transplant. Proc. pmid:10856596
Fritsche L et al. Conversion to mycophenolate mofetil for chronic progressive deterioration of renal allograft function: first clinical experiences in 44 patients. 1998 Transplant. Proc. pmid:9636481
Miura S et al. Effect of tacrolimus on the outcome of renal transplantation with donor-specific blood transfusion. 1998 Transplant. Proc. pmid:9636492
Mehra MR et al. Corticosteroid weaning in the tacrolimus and mycophenolate era in heart transplantation: clinical and neurohormonal benefits. 2004 Transplant. Proc. pmid:15686716
Dallos G et al. Results and complications after living related kidney transplantation in Hungary: 30 years' experience. 2010 Jul-Aug Transplant. Proc. pmid:20692470
Flavin T et al. Initial experience with FK 506 as an immunosuppressant for nonhuman primate recipients of cardiac allografts. 1991 Transplant. Proc. pmid:1703701